Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98

[1]  B. O’Malley,et al.  Development of potent small-molecule inhibitors to drug the undruggable steroid receptor coactivator-3 , 2016, Proceedings of the National Academy of Sciences.

[2]  M. Fernö,et al.  Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer , 2016, PloS one.

[3]  D. Sgroi,et al.  Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  M. Fernö,et al.  The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  A. Giobbie-Hurder,et al.  Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy , 2012, Acta oncologica.

[6]  R. Gelber,et al.  Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  A. Hill,et al.  AIB1:ERα Transcriptional Activity Is Selectively Enhanced in Aromatase Inhibitor–Resistant Breast Cancer Cells , 2012, Clinical Cancer Research.

[8]  B. O’Malley,et al.  Small molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1. , 2011, Molecular endocrinology.

[9]  M. Fernö,et al.  AIB1 is a predictive factor for tamoxifen response in premenopausal women. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Satoru Takahashi,et al.  Predictors of response to exemestane as primary endocrine therapy in estrogen receptor–positive breast cancer , 2009, Cancer science.

[11]  A. Giobbie-Hurder,et al.  Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. , 2009, The New England journal of medicine.

[12]  A. Giobbie-Hurder,et al.  Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer , 2009, Clinical trials.

[13]  D. Rimm,et al.  Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome , 2009, Breast Cancer Research and Treatment.

[14]  Simak Ali,et al.  Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifen , 2009, Nature.

[15]  Simak Ali,et al.  Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifen , 2008, Nature.

[16]  N. Kondo,et al.  Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer. , 2008, Endocrine-related cancer.

[17]  M. Fernö,et al.  Access to the Published Version May Require Journal Subscription. Published with Permission From: Springer Epidermal Growth Factor Receptor (egfr) and the Estrogen Receptor Modulator Amplified in Breast Cancer (aib1) for Predicting Clinical Outcome after Adjuvant Tamoxifen in Breast Cancer , 2022 .

[18]  C. Begg,et al.  Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. , 2008, Journal of the National Cancer Institute.

[19]  P. Neven,et al.  Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  John M.S. Bartlett,et al.  Amplified in Breast Cancer 1 in Human Epidermal Growth Factor Receptor–Positive Tumors of Tamoxifen-Treated Breast Cancer Patients , 2007, Clinical Cancer Research.

[21]  B. Rasmussen,et al.  Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays , 2006, Journal of Clinical Pathology.

[22]  A. Harris,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British Journal of Cancer.

[23]  D G Altman,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British journal of cancer.

[24]  E. McDermott,et al.  Associations and Interactions between Ets-1 and Ets-2 and Coregulatory Proteins, SRC-1, AIB1, and NCoR in Breast Cancer , 2005, Clinical Cancer Research.

[25]  W. Sellers,et al.  High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. , 2004, Cancer cell.

[26]  R. Schiff,et al.  Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.

[27]  T. Toyama,et al.  Clinical Significance of AIB1 Expression in Human Breast Cancer , 2003, Breast Cancer Research and Treatment.

[28]  Hideaki Kurioka,et al.  Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis , 2003, Cancer.

[29]  S. Hilsenbeck,et al.  Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. , 2003, Journal of the National Cancer Institute.

[30]  Baljit Singh,et al.  Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue , 2001, Breast Cancer Research and Treatment.

[31]  M. Southey,et al.  Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. , 2001, Cancer research.

[32]  P. Meltzer,et al.  AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. , 1997, Science.

[33]  R. Conroy,et al.  AIB1:ERalpha transcriptional activity is selectively enhanced in AI-resistant breast cancer cells , 2012 .

[34]  S. Hilsenbeck,et al.  The p160 ER co-regulators predict outcome in ER negative breast cancer , 2011, Breast Cancer Research and Treatment.

[35]  R. Gelber,et al.  Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. , 2008, The Lancet. Oncology.